Fig. 1From: Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stageStudy flow diagram according to the eligible criteria. After 321 of 798 patients were excluded, data from 477 patients were analysed retrospectively. The propensity score matching was performed between XELOX group and S-1 groupBack to article page